Pre-made Lirilumab benchmark antibody ( Whole mAb, anti-KIRD2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-316
Anti-KIRD2 therapeutic antibody (Pre-made Lirilumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-KIRD2 therapeutic antibody (Pre-made Lirilumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center|
|Conditions Active||Chronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer|
|Conditions Discontinued||Acute myeloid leukaemia;Hepatitis C;Haematological malignancies;Multiple myeloma;Lymphoma|
|Development Tech||Medarex UltiMAb Mouse|